Transforming the treatment paradigm in the
costliest cancer to become the new standart-of-care in a market that has seen little innovation in >30 years
Restoring anti-tumor responses with an oral immune training agent to boost efficacy of immunotherapies for the 80% of patients unable to benefit today
Reprogramming Salmonella with bespoke synthetic circuits to deliver diverse therapeutic cargo for difficult-to-treat cancers
Bladder cancer is one of the costliest cancers to treat with 550.000 new cases annually worldwide, representing 5% of all new cases in the US. The clinical staging is determined by the depth of tumor invasion into the bladder wall and more than 70% of patients are diagnosed at an early stage, known as non-muscle invasive bladder cancer (NMIBC). Despite early diagnosis, and treatment with standard-of-care Bacillus Calmette-Guerin (BCG), up to 80% of patients recur increasing the risk of progression. Because of bladder cancer’s high incidence, frequent recurrences, and low number of treatment options, a huge unmet medical need remains.
Approximately 80% of cancer patients are underserved by advanced immunotherapies today and majority of therapies in development do not address underlying cancer-related innate immune dysfunction.
Salmonella as a first-in-class oral immune training agent has the potential to restore immune fitness unlocking the missing link in the anti-tumor immunity cycle in an indication agnostic setting.
Proprietary synthetic biology platform for novel immunotherapies designed to deliver diverse cargo families ranging from production of therapeutic molecules within the tumor microenvironment to targeted, localized delivery of nucleic acids.
The Company’s pipeline is designed to unlock a new generation of immuno-oncology therapeutics by re-engineering evolution into a synthetic biology platform. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
Lead oncology program entering the clinic in the US in H2 2023
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
First-in-class oral training agent ready to enter the clinic in late-2023
Seeking partnership and licensing opportunities to combine with advanced immunotherapies
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
Discovery cargo-delivery platform
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
Oral, bivalent vaccine funded by Wellcome Trust